Approval · Notice of Compliance 14357 · 2013
MAXALT: Notice of Compliance 14357
Issued May 9, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14357
- Date
- May 9, 2013
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of pediatric pK and clinical data to the Action and Clinical Pharmacology section of the Product Monograph
- Therapeutic class
- 5-ht1 receptor agonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MAXALT | Not yet assigned | — |
| MAXALT RPD | Not yet assigned | — |
Medicinal ingredients
- RIZATRIPTAN BENZOATE 5 MG per TAB
- RIZATRIPTAN BENZOATE 10 MG per TAB